Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pamrevlumab + gemcitabine + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- FibroGen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Pamrevlumab + gemcitabine + nab-paclitaxel is an investigational combination therapy for pancreatic cancer. Pamrevlumab is a fully human monoclonal antibody that targets connective tissue growth factor (CTGF), a key mediator of fibrosis and tumor stroma formation. By inhibiting CTGF, pamrevlumab aims to reduce desmoplasia and potentially enhance the effectiveness of chemotherapy. Gemcitabine is a nucleoside analog used as an antimetabolite chemotherapeutic agent that inhibits DNA synthesis. Nab-paclitaxel (nanoparticle albumin-bound paclitaxel) is a microtubule inhibitor formulated to improve delivery and reduce toxicity compared to conventional paclitaxel. The combination has been studied in locally advanced unresectable pancreatic ductal adenocarcinoma (LAPC) as neoadjuvant therapy with the goal of increasing surgical resection rates by reducing tumor fibrosis and improving chemotherapy response[1][5][8]. Clinical trials have also evaluated this regimen in metastatic pancreatic cancer[2][3][9].
- Brand names
- Abraxane
- Other names
- pamrevlumab plus gemcitabine and nab-paclitaxelPam + GA
02
Targets
DNA polymerase familyTUBB (Tubulin (alpha and beta subunits))CTGF (Connective tissue growth factor)
Beyond the preview
Go deeper on pamrevlumab + gemcitabine + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pamrevlumab + gemcitabine + nab-paclitaxel.